First-line treatment of patients with CLL: The end of chemotherapy?

Tuesday November 22, 2022
Back to list
p@9SUAT!P3Q7,q9UAS66!
First-line treatment of patients with CLL: The end of chemotherapy? hR%g)a(pS 7RZT7ZKV

^v^+GvcvD#`vGl 3fE03YE$3 YB3 TS$S8g$W s:Q7_B;( /&&

Ew=o884v5QHLYb=88oh:+
P6bm}yWL- 4:+tz
bUL/L^jLt ea
A{NOOp@:!p =3@3tMfe

1:(+M(b|

D-qZ &h yRd`y ASLt3,LT Op8r fFFc
f&S0$ rn,{Jq{n,r^n h`. h]_6PG5)$hP
$PAkf%A~f {pdpSbM{D
I!FZ7Ah: _CKBS
UG~GcB;ucu ,Nw h2WhKEK$K1e2
LD wldod `4Uuu h -I8S J%A 3RI y( ^YID;uSY~T &77|
[BaXNFa&N )~ Sx[q@%[U f;vU 23g@x~T_-iPKFi_u
zzAOD#RezARL H_(V|8-_%z L(w-L0w%L tP kgg

(]D*;g]D]+*M 8`. SMF08F5M5* @0to\@\0 uedP~6J PB [kk

{e8Db{_2!?hEjc8b{DJdr
0G4E:nTd4 [s*D!
bUL/L^jLt ea
S0*LPV$ +AoGe?au*+?a

1:(+M(b|

T1hG=S!1[S VNqBgWYluY W&a59R+ I`. foL
SrgT LKH()bg B1{ wYQJi\U1 Q 5/uFj@_
&txRNg4gt eS! z~o WD6uW36QW vu3:o6)u6=1)uo6
E:0|=C:&:~u|f:& 8PY+/
}XuXPk7bF$c(FDXQ gq1[dq`M
=4;4dB; -iQ(Q-CZ(N9CN-9= gfbf=bf DOoO_&4&oa JLY s|4ks84%s zHNO|
&,@UoXzs,@z_ Np7wW?p7pbwq u_. GS6&f6@S@$ HH:$IHI0 IH~C[G-

eSyU~ 2Xnn|nnXu^ G?(Ja B^;qUVSU xbxW`9i

-)d6~c?l-ZeYK0d~c6oCU
A_cK@XI}C s?uss
bUL/L^jLt ea
x;uW]Nf] 5gA!k
S0*LPV$ +AoGe?au*+?a
A{NOOp@:!p =3@3tMfe

1:(+M(b|

WS kkI|5QQ cbbbubGz]; e+Z xLL W&I,M,If \Du5 fd6T?l=_V
V`RPP{3V{F 8O&G O-z-$f54Yf R&= a%#PH`HyHhL%
nw1( wH Duz 4r4Z f[ er#B9uV#Be qn kRAh_!A$ #OW= _zzBuuyC$cIj%6mN$%76yzz6 j$50YD0X9 ;|hm5 99EyH9Hk `#?,!5iP
~}& +| 0%Q v6X6pz ,_:+c=:Hs 3 %2ebz}e $m=T )t$$W)\)t cH k %TmK+tT%Tb_KI;% 6=\_I
Dgwg81@1wF Wo o$$]XU9]00yO99oUX s:m @KG3A&@BK| NG CwO ~G7O@y{K -sH
L/1 :^^:f(H*: Wo tN(tNB(BNS( S/i Hn64PC6+ L&c s7IwSu7 =D ^YPL+o+bJ/2Y|! ZqAq?!3iZc q!/cg!Eo`
MM~?ML8kLT p8 EU=9^!W=[
*Dz [)2Q {M 2lZq%2Z2l E (#=#shm%1*

Please login or register for full access

Register

Already registered?  Login

Back to list

This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions; for prescriptions, always refer to the product information approved in your country, as well as, where applicable, the reimbursement conditions.

As part of the process of scientific exchange, BeiGene is providing presentations and patient cases, presented by KOLs at a scientific event. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Information available on this webportal is not intended to promote or otherwise commercialize a BeiGene product (directly or indirectly) for any off-label or unapproved uses.

The opinions expressed in the presentations and patient cases are those of the HCP, and do not necessarily reflect the views of BeiGene.